Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naive patients-A retrospective register-based cohort study in Finland and Sweden.

ABSTRACT:

Background

Plaque psoriasis (PsO) requires long-term treatment for symptom control and remission; thus, a long-term pharmacological intervention is necessary. Treatment persistence reflects long-term therapeutic effectiveness and tolerance.

Objectives

This study investigates drug persistence and compares treatment discontinuation rates across biologic agents and apremilast used by PsO patients in Finland and Sweden.

Methods

This retrospective register-based cohort study included bio-naïve patients (≥18 years) with moderate-to-severe PsO, who initiated treatment with abatacept, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab or apremilast during 2008-2020 in Finland or Swed

SUBMITTER: Tskhvarashvili G 

PROVIDER: S-EPMC11862870 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature